Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs progression-free survival, but not overall survival

Bevacizumab treatment in patients with progressive glioblastoma, despite prolonged progression-free survival, does not confer a survival advantage, report scientists.